What is the intention with skinny labels and second medical use patents?
- Published in:
- Journal of Generic Medicines, 2014, v. 11, n. 3/4, p. 166, doi. 10.1177/1741134315587063
- By:
- Publication type:
- Article
Works matching DE "ACTAVIS PLC (2013-2015)"
Results: 16
1
2
EU Case Reports.
- Published in:
- Journal of Generic Medicines, 2011, v. 8, n. 2, p. 123, doi. 10.1177/1741134311408273
- By:
- Publication type:
- Article
3
A PRESCRIPTION FOR THE FUTURE: REVERSE-PAYMENT SETTLEMENTS IN THE WAKE OF FTC v. ACTAVIS PHARMACEUTICALS.
- Published in:
- Notre Dame Journal of Law, Ethics & Public Policy, 2015, v. 29, n. 2, p. 549
- By:
- Publication type:
- Article
4
SMC recommends OZURDEX® for DMO.
- Published in:
- Ophthalmology Times Europe, 2015, v. 11, n. 5, p. 42
- Publication type:
- Article
5
The Opioid Epidemic: Fixing a Broken Pharmaceutical Market.
- Published in:
- Harvard Law & Policy Review, 2017, v. 11, n. 2, p. 463
- By:
- Publication type:
- Article
6
An assessment of the UK approach to parametric claims after Actavis v Eli Lilly.
- Published in:
- Journal of Intellectual Property Law & Practice, 2021, v. 16, n. 2, p. 109, doi. 10.1093/jiplp/jpaa210
- By:
- Publication type:
- Article
7
Abstract functional combinations after Actavis: what future?
- Published in:
- Journal of Intellectual Property Law & Practice, 2016, v. 11, n. 3, p. 212, doi. 10.1093/jiplp/jpw001
- By:
- Publication type:
- Article
8
Big Pharma, Big Problems: COVID-19 Heightens Patent-Antitrust Tension Caused by Reverse Payments.
- Published in:
- Seattle University Law Review, 2021, v. 44, n. 2, p. 601
- By:
- Publication type:
- Article
9
Patently unclear.
- Published in:
- Chemistry & Industry, 2016, v. 80, n. 8, p. 37, doi. 10.1002/cind.808_14.x
- Publication type:
- Article
10
BAD MEDICINE: FTC v. ACTAVIS, INC. AND THE MISSED OPPORTUNITY TO RESOLVE THE PAY-FOR-DELAY PROBLEM.
- Published in:
- Maryland Law Review, 2014, v. 73, n. 4, p. 1240
- By:
- Publication type:
- Article
11
Actavis buys Botox maker Allergan for US$66bn.
- Published in:
- TCE: The Chemical Engineer, 2014, n. 882, p. 8
- Publication type:
- Article
12
Actavis buys Forest for US$25bn.
- Published in:
- TCE: The Chemical Engineer, 2014, n. 873, p. 8
- Publication type:
- Article
13
Redrawing the Line Between Patent Rights and Antitrust Law: How the U.S. Supreme Court's Over- Extension of Antitrust Law Harms Patent Holders, Damages Innovation, and Discourages Settlements [FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013)].
- Published in:
- Washburn Law Journal, 2014, v. 53, n. 2, p. 365
- By:
- Publication type:
- Article
14
THE PRICE TAG OF “PAY-FOR-DELAY”.
- Published in:
- Columbia Science & Technology Law Review, 2021, v. 23, n. 1, p. 1
- By:
- Publication type:
- Article
15
Seven days: 14-20 November.
- Published in:
- Nature, 2014, v. 515, n. 7527, p. 316, doi. 10.1038/515316a
- Publication type:
- Article
16
$675 million for MRSA antibiotic.
- Published in:
- Nature Biotechnology, 2014, v. 32, n. 11, p. 1070, doi. 10.1038/nbt1114-1070c
- Publication type:
- Article